Nervenheilkunde 2024; 43(07/08): 424-428
DOI: 10.1055/a-2318-5701
Schwerpunkt

Umfassende Versorgung bis zuletzt

Lebensende mit der Parkinson-KrankheitComprehensive care until the endEnd of life with Parkinson’s disease
Anna J. Pedrosa
1   Klinik für Neurologie, Universitätsklinikum Gießen und Marburg
,
David J. Pedrosa
1   Klinik für Neurologie, Universitätsklinikum Gießen und Marburg
2   Center for Mind, Brain and Behavior, Philipps-Universität Marburg
› Author Affiliations

ZUSAMMENFASSUNG

Die Parkinson-Krankheit ist eine neurodegenerative Erkrankung, die mit erhöhter Mortalität einhergeht. Die Betroffenen leiden im Verlauf der Krankheit unter einer Vielzahl von motorischen und nicht motorischen Symptomen, die ihre Lebensqualität stark beeinträchtigen können. Durch die Umsetzung von multiprofessionellen Strategien, einschließlich einer frühzeitigen Integration von palliativen Versorgungsstrukturen, kann eine holistische und individualisierte Betreuung gewährleistet werden. Dadurch ist es möglich, Probleme der Betroffenen rechtzeitig zu erkennen und angemessen zu behandeln. Die meisten Menschen mit der Parkinson-Krankheit möchten zu Hause versterben; jedoch besprechen sie ihre Wünsche für das Lebensende nur selten mit ihren Primärversorgern. Durch eine proaktive Gesprächsführung über das Lebensende können Versorger, Bedürfnisse identifizieren, patientenzentrierte Maßnahmen umzusetzen und Autonomie stärken. Dies beinhaltet auch die Erstellung von Vorausplänen für medizinische Notfälle, was sowohl den Patientenwillen nach Eintreten der Einwilligungsunfähigkeit stärkt als auch die Belastung für Familienmitglieder verringert.

ABSTRACT

Parkinson’s disease is a neurodegenerative disorder associated with increased mortality. Throughout the course of the disease, individuals suffer from a variety of motor and non-motor symptoms that can greatly impair their quality of life. By implementing multiprofessional strategies, including early integration of palliative care structures, holistic and individualised care can be ensured. This enables the timely recognition and appropriate treatment of patients’ problems. Most people with Parkinson’s disease wish to die at home; however, they rarely discuss these end-of-life wishes with their primary healthcare providers. By engaging in proactive end-of-life conversations, healthcare staff can identify needs, implement patient-centred measures and enhance autonomy. This includes making advance care plans for medical emergencies, which both strengthens the patient’s will in the event of incapacity and reduces the burden on family members.



Publication History

Article published online:
17 July 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • Literatur

  • 1 Macleod AD, Taylor KS, Counsell CE. Mortality in Parkinson’s disease: a systematic review and meta-analysis.. Movement Disorders 2014; 29 (13) 1615-22
  • 2 Xu J, Gong D, Man C. et al Parkinson’s disease and risk of mortality: meta-analysis and systematic review.. Acta Neurologica Scandinavica 2014; 129 (02) 71-9
  • 3 Kluger BM, Fox S, Timmons S. et al Palliative care and Parkinson’s disease: meeting summary and recommendations for clinical research.. Parkinsonism & related disorders 2017; 37: 19-26
  • 4 Feigin VL, Nichols E, Alam T. et al Global, regional, and national burden of neurological disorders, 1990–2016 a systematic analysis for the Global Burden of Disease Study 2016.. The Lancet Neurology 2019; 18 (05) 459-80
  • 5 World Health Organization. Parkinson disease: a public health approach: technical brief. Genf, 2022
  • 6 Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review.. Archives of neurology 2002; 59 (11) 1724-8
  • 7 Jankovic J, McDermott M, Carter J. et al Variable expression of Parkinson’s disease: A base-line analysis of the DAT ATOP cohort.. Neurology 1990; 40 (10) 1529
  • 8 Siderowf A, Concha-Marambio L, Lafontant D-E. et al Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study.. The Lancet Neurology 2023; 22 (05) 407-17
  • 9 Aarsland D, Creese B, Politis M. et al Cognitive decline in Parkinson disease.. Nature Reviews Neurology 2017; 13 (04) 217-31
  • 10 Höglinger GU, Adler CH, Berg D. et al A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria.. The Lancet Neurology 2024; 23 (02) 191-204
  • 11 Akbar U, McQueen RB, Bemski J. et al Prognostic predictors relevant to end-of-life palliative care in Parkinson’s disease and related disorders: a systematic review.. Journal of Neurology, Neurosurgery & Psychiatry 2021; 92 (06) 629-36
  • 12 Beyer M, Herlofson K, Årsland D. et al Causes of death in a community-based study of Parkinson’s disease.. Acta Neurologica Scandinavica 2001; 103 (01) 7-11
  • 13 Pennington S, Snell K, Lee M. et al The cause of death in idiopathic Parkinson’s disease.. Parkinsonism & related disorders 2010; 16 (07/08) 434-7
  • 14 Fall PA, Saleh A, Fredrickson M. et al Survival time, mortality, and cause of death in elderly patients with Parkinson’s disease. A 9-year follow-up.. Movement disorders: official journal of the Movement Disorder Society 2003; 18 (11) 1312-6
  • 15 Kempster PA, O’Sullivan SS, Holton JL. et al Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study.. Brain 2010; 133 (06) 1755-62
  • 16 Mahes A, Macchi ZA, Martin CS. et al The “Surprise Question” for Prognostication in People With Parkinson’s Disease and Related Disorders.. Journal of Pain and Symptom Management 2024; 67 (01) e1-e7
  • 17 Postuma RB, Berg D, Stern M. et al MDS clinical diagnostic criteria for Parkinson’s disease.. Movement disorders 2015; 30 (12) 1591-601
  • 18 Höglinger G, Trenkwalder C. et al Parkinson-Krankheit, S2k-Leitlinie.. Berlin: Deutsche Gesellschaft für Neurologie 2023
  • 19 Schapira AH, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease.. Nature Reviews Neuroscience 2017; 18 (07/08) 435-50
  • 20 Saleem TZ, Higginson IJ, Chaudhuri KR. et al Symptom prevalence, severity and palliative care needs assessment using the Palliative Outcome Scale: a cross-sectional study of patients with Parkinson’s disease and related neurological conditions.. Palliative Medicine 2013; 27 (08) 722-31
  • 21 Schrag A, Bohlken J, Dammertz L. et al Widening the spectrum of risk factors, comorbidities, and prodromal features of Parkinson disease.. JAMA neurology 2023; 80 (02) 161-71
  • 22 Wasner G, Deuschl G. Pains in Parkinson disease — many syndromes under one umbrella.. Nature Reviews Neurology 2012; 08 (05) 284-94
  • 23 Siciliano M, Trojano L, Santangelo G. et al Fatigue in Parkinson’s disease: a systematic review and meta-analysis.. Movement Disorders 2018; 33 (11) 1712-23
  • 24 Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM. et al The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease.. Movement Disorders 2011; 26 (03) 399-406
  • 25 van Munster M, Pedrosa AJ, Künkler C. et al The Quality in Quality of Life in Parkinson’s Disease: A Qualitative Meta-Synthesis.. Mov Dis 2024 DOI: 10.1002/mdc3.14063
  • 26 Stührenberg M, Berghäuser CS, van Munster M. et al Measuring quality of life in Parkinson’s disease — A call to rethink conceptualizations and assessments.. Journal of Personalized Medicine 2022; 12 (05) 804
  • 27 Houska A, Loučka M. Patients’ autonomy at the end of life: a critical review.. Journal of pain and symptom management 2019; 57 (04) 835-45
  • 28 Klietz M, Tulke A, Müschen LH. et al Impaired quality of life and need for palliative care in a German cohort of advanced Parkinson’s disease patients.. Frontiers in neurology 2018; 09: 120
  • 29 Pedrosa AJ, Feldmann S, Klippel J. et al Factors Associated with Preferred Place of Care and Death in Patients with Parkinson’s Disease: A Cross-Sectional Study.. Journal of Parkinson’s Disease 2024: 1-11
  • 30 Moens K, Houttekier D, Van den Block L. et al Place of death of people living with Parkinson’s disease: a population-level study in 11 countries.. BMC palliative care 2015; 14: 1-9
  • 31 Billingham MJ, Billingham J. Congruence between preferred and actual place of death according to the presence of malignant or non-malignant disease: a systematic review and meta-analysis.. BMJ supportive & palliative care 2013; 03 (02) 144-54
  • 32 Ali M, Capel M, Jones G. et al The importance of identifying preferred place of death.. BMJ supportive & palliative care 2019; 09 (01) 84-91
  • 33 Heinzel S, Berg D, Binder S. et al Do we need to rethink the epidemiology and healthcare utilization of Parkinson’s disease in Germany?. Frontiers in neurology 2018; 09: 500
  • 34 Pedrosa AJ, van Munster M, Timmermann L. et al Safety perception in patients with advanced idiopathic Parkinson’s disease–a qualitative study.. Frontiers in Aging Neuroscience 2023: 15
  • 35 Chen Y, Zhang R, Lou Y. et al Facilitators and barriers to the delivery of palliative care to patients with Parkinson’s disease: a qualitative study of the perceptions and experiences of stakeholders using the socio-ecological model.. BMC Health Services Research 2023; 23 (01) 215
  • 36 Rosqvist K, Kylberg M, Löfqvist C. et al Perspectives on care for late-stage Parkinson’s disease.. Parkinson’s Disease 2021: 2021
  • 37 Okunoye O, Kojima G, Marston L. et al Factors associated with hospitalisation among people with Parkinson’s disease – a systematic review and meta-analysis.. Parkinsonism & Related Disorders 2020; 71: 66-72
  • 38 Gerlach OH, Winogrodzka A, Weber WE. Clinical problems in the hospitalized Parkinson’s disease patient: systematic review.. Movement Disorders 2011; 26 (02) 197-208
  • 39 Fründt O, Hanff A-M, Mai T. et al Scoping-Review zur stationären Langzeitpflege von Menschen mit idiopathischem Parkinson in Deutschland.. DGNeurologie 2022; 05 (05) 345-54
  • 40 Boersma I, Jones J, Carter J. et al Parkinson disease patients’ perspectives on palliative care needs: What are they telling us?. Neurology Clinical Practice 2016; 06 (03) 209-19
  • 41 DGP/DHPV 2009. www.dgpalliativmedizin.de/allgemein/allgemeine-ambulante-palliativversorgung-aapv.html Stand: 23.05.2014
  • 42 World Health Organization. Fact Sheets – Palliative Care. Genf, 2023
  • 43 Moens K, Higginson IJ, Harding R. et al Are there differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight non-cancer conditions? A systematic review.. Journal of pain and symptom management 2014; 48 (04) 660-77
  • 44 Gärtner J, Wedding U, Alt-Epping B. Frühzeitige spezialisierte palliativmedizinische Mitbehandlung.. Die Onkologie 2015; 21 (12) 1182-8
  • 45 Kluger BM, Miyasaki J, Katz M. et al Comparison of integrated outpatient palliative care with standard care in patients with Parkinson disease and related disorders: a randomized clinical trial.. JAMA neurology 2020; 77 (05) 551-60
  • 46 Klietz M, Öcalan Ö, Schneider N. et al Advance directives of German people with Parkinson’s disease are unspecific in regard to typical complications.. Parkinson’s Disease 2019: 2019
  • 47 Kwak J, Wallendal MS, Fritsch T. et al Advance care planning and proxy decision making for patients with advanced Parkinson disease.. Southern medical journal 2014; 107 (03) 178-85
  • 48 Sudore RL, Lum HD, You JJ. et al Defining advance care planning for adults: a consensus definition from a multidisciplinary Delphi panel.. Journal of pain and symptom management 2017; 53 (05) 821-32. e1
  • 49 Garon M, Weck C, Rosqvist K. et al A systematic practice review: Providing palliative care for people with Parkinson’s disease and their caregivers.. Palliative Medicine 2024; 38 (01) 57-68
  • 50 Götze K, Feddersen B, in der Schmitten J. et al Advance Care Planning in Germany.. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2023; 180: 127-32